Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
Public ClinicalTrials.gov record NCT02911142. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
Study identification
- NCT ID
- NCT02911142
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 17 participants
Conditions and interventions
Conditions
Interventions
- 18FDG-PET scan Diagnostic Test
- Bone marrow biopsy Procedure
- Bronchoscopy Diagnostic Test
- CT of neck, chest, abdomen and pelvis Diagnostic Test
- CXR: PA/lat/decub Diagnostic Test
- Cyclophosphamide Drug
- Doxorubicin Drug
- EKG Diagnostic Test
- Echocardiogram Diagnostic Test
- Endoscopy Diagnostic Test
- Etoposide Drug
- Lenalidomide Drug
- MRI Brain Diagnostic Test
- Prednisone Drug
- Rituximab Drug
- Ultrasound Diagnostic Test
- Vincristine Drug
Diagnostic Test · Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2, 2017
- Primary completion
- Sep 30, 2024
- Completion
- Sep 30, 2027
- Last update posted
- Jul 27, 2025
2017 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02911142, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2025 · Synced Apr 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02911142 live on ClinicalTrials.gov.